Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $1.0 million.

  • Atara Biotherapeutics' Cash from Financing Activities fell 9707.48% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 7419.42%. This contributed to the annual value of $59.3 million for FY2024, which is 284935.32% up from last year.
  • Per Atara Biotherapeutics' latest filing, its Cash from Financing Activities stood at $1.0 million for Q3 2025, which was down 9707.48% from $15.3 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Cash from Financing Activities high stood at $35.8 million for Q3 2024, and its period low was -$328000.0 during Q4 2024.
  • Its 4-year average for Cash from Financing Activities is $8.7 million, with a median of $1.0 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Atara Biotherapeutics' Cash from Financing Activities was 1730817.31% (2024), while the steepest drop was 16878.98% (2024).
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Cash from Financing Activities stood at $32.3 million in 2022, then crashed by 95.32% to $1.5 million in 2023, then tumbled by 121.69% to -$328000.0 in 2024, then skyrocketed by 419.21% to $1.0 million in 2025.
  • Its Cash from Financing Activities was $1.0 million in Q3 2025, compared to $15.3 million in Q2 2025 and -$250000.0 in Q1 2025.